Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.47 |
| ▸ | BRD2 | P25440 | 5/20 | 0.47 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.42 |
| ▸ | MLYCD | O95822 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14196935 | 0.77 | BRD4 (0.61) | BRD4BRD2BRD3GPR55CREBBP | |
| SCHEMBL5553073 | 0.74 | BRD4 (0.53) | BRD4BRD2BRD3GPR55CREBBP | |
| SCHEMBL5553096 | 0.72 | CYP2D6 (0.46) | — | |
| SCHEMBL5550006 | 0.72 | CYP2D6 (0.46) | — | |
| SCHEMBL5550009 | 0.72 | CYP2D6 (0.46) | — | |
| SCHEMBL5554000 | 0.72 | BMPR1B (0.43) | — | |
| SCHEMBL5555173 | 0.71 | BMPR1B (0.42) | — | |
| SCHEMBL5554053 | 0.71 | BMPR1B (0.42) | — | |
| SCHEMBL5553082 | 0.71 | CYP2D6 (0.47) | — | |
| SCHEMBL5549400 | 0.71 | CYP2D6 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756058-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005105744-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. | 2005-11-10 | — | — | WO | claimed |
| US-20050245543-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2005-11-03 | — | — | US | claimed |
| US-20050245543-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245543-A1 | Histamine-3 receptor antagonists | HRH3, HRH4, HRH2 | BRD4 1705/4885BRD2 2522/4885BRD3 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.